Orchard therapeutics™

2021 JP Morgan Presentation

Bobby Gaspar, M.D., Ph.D.

Chief executive officer

January 13, 2021

Forward Looking Statements

Certain information set forth in this presentation and in statements made orally during this presentation contains “forward-looking statements”. Except for statements of historical fact, information contained herein constitutes forward-looking statements and may include, but is not limited to, the Company’s expectations regarding: (I) the safety and efficacy of Libmeldy and its product candidates; (II) the expected development of the Company’s business and product candidates; (III) the timing of regulatory submissions for approval of its product candidates; (IV) the timing of interactions with regulators and regulatory submissions related to ongoing and new clinical trials for its product candidates; (V) the timing of announcement of preclinical and clinical data for its product candidates and the likelihood that such data will be positive and support further development and regulatory approval of these product candidates; (VI) the timing and likelihood of approval of such product candidates by the applicable regulatory authorities; (VII) the adequacy of the Company’s supply chain and ability to commercialize Libmeldy, including the ability to secure adequate pricing and reimbursement to support continued development and commercialization of Libmeldy; (VIII) execution of the Company’s vision and growth strategy, including with respect to global growth; (IX) the size and value of potential markets for the Company’s product candidates; and (X) projected financial performance and financial condition, including the sufficiency of the Company’s cash and cash equivalents to fund operations in future periods and future liquidity, working capital and capital requirements. The words “may,” “should,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts," “potential,” “continue,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements are provided to allow investors the opportunity to understand management’s beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment.

These statements are neither promises nor guarantees of future performance. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which include, without limitation, the severity of the impact of the COVID-19 pandemic on the Company’s business, including on preclinical and clinical development and commercial programs, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or results expressed or implied by such forward-looking statements. You are cautioned not to place undue reliance on forward-looking statements. These statements are subject to a variety of risks and uncertainties, many of which are beyond the Company’s control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. For additional disclosure regarding these and other risks faced by the Company, see the disclosure contained in the Company’s public filings with the U.S. Securities and Exchange Commission (the “SEC”), including in the Company’s quarterly report on Form 10-Q filed with the SEC on November 3, 2020, as well as subsequent filings and reports filed with the SEC. These forward-looking statements speak only as of the date of this presentation. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.

Orchard therapeutics

Curing the incurable

The potential of HSC gene therapy

Orchard therapeutics™

A Vision for Long-term Growth and Value Creation



Orchard therapeutics

We Are Delivering Now and Building for the Future



Orchard therapeutics™

HSC Gene Therapy Offers a Highly Differentiated Approach





Brain
GI
High area of focus

Other Organ Systems
Areas for potential future expansion

Literature references: Alessia Capotondo, Rita Milazzo, Letterio Salvatore Politi, Angelo Quattrini, Alessio Palini, Tiziana Plati, Stefania Merella, Alessandro Nonis, Clelia di Serio, Eugenio Montini, Luigi Naldini, and Alessandra Biffi, PNAS September 11, 2012 109 (37) 15018-15023; https://doi.org/10.1073/pnas.1205858109; Tissue macrophages: heterogeneity and functions, Siamon Gordon and Annette Plüddemann, BMC Biology 2017 15:53, 29 June 2017

Orchard therapeutics™

Durability of Response and Safety Demonstrated via Longest Patient Follow-up



Patients treated in the development phase, including in clinical trials and under pre-approval access (defined as any form of pre-approval treatment outside of a company-sponsored clinical trial, including, but not limited to, compassionate use, early access, hospital exemption or special license).
Data based on in-house data as of November 2020. Data include all patients treated with CD34+ hematopoietic stem cells transduced ex vivo with vector of interest.

Orchard therapeutics

Improving the HSC Gene Therapy Manufacturing Process

Lentiviral Vector Manufacturing

Drug Product Manufacturing (Cell Processing)

1 Manufacture gene-specific lentiviral vector

2 Genetically modify HSPCs with lentiviral vector

3

	Technology innovations
1 **Vector Production**	**Scalable suspension culture with stable producer cell line**
2 **Stem Cell Transduction**	**Transduction enhancing compounds**
3 **Drug product process**	**Fully closed, automated cell processing**

Orchard therapeutics

Applying Commercial Strategy to Launch Gene Therapies Globally

Leverage for Libmeldy and future launches

Enable Patient ID & Diagnostics

Multi-pronged diagnostics initiatives and newborn screening in EU and U.S.

Expand Geographic Footprint

Qualifying leading centers with transplant and disease area experience

Establish Global Supply Network

Inventory, capacity and logistics of supply

Secure Market Access

Multi-stakeholder engagement with flexible payment models

Orchard therapeutics

HSC Gene Therapy: Meeting the Need in Severe Neurodegenerative Disorders

Orchard therapeutics

Clinical Efficacy in Multiple Devastating, Rapidly Progressive Diseases

Late Infantile MLD



LI, late infantile; EJ, early juvenile CI, confidence interval; GMFM, gross motor function measurement; MLD, metachromatic leukodystrophy;
Both LI and EJ patients (EJ not shown) achieved a statistically significant difference on the co-primary endpoint of improvement of >10% of the total GMFM score in treated subjects when compared to the Natural History cohort at Year 2, and these were maintained through Year 3. Note: vertical error bars are standard error of the adjusted mean; P-values are from a two-sided 5% hypothesis test with null hypothesis of ≤ 10% difference

MPS-I



MPS-I data presented May 15, 2020 at ASGCT annual meeting

Orchard therapeutics

New Clinical Data from Three Neurodegenerative Programs Coming at WORLD*Symposium*™

Nine Orchard Abstracts Accepted Showcasing Strength of HSC Approach

OTL-203 for MPS-I	**New clinical results from fully enrolled POC trial**
OTL-201 for MPS-IIIA	**Results from first three patients treated**
OTL-200 for MLD	**NBS, market access and cryopreservation data**

Growing Neurodegenerative Portfolio from Rare to Larger Indications



*Other undisclosed development programs

Orchard therapeutics

HSC Gene Therapy Is Highly Suited for GRN-FTD: a Large and Growing Opportunity

THE OPPORTUNITY

OTL-204 for GRN-FTD

- Haploinsufficiency of progranulin *(GRN)* strongly associated with FTD (~5% of cases)
- Mutation known to have high penetrance
- Up to 2,500 GRN-FTD prevalent patients in U.S. and EU[1-3]
- ~800 new cases U.S. / EU per year[1-3]

OUR UNIQUE POSITIONING

HSC gene therapy has demonstrated potential to treat diseases of the brain

- Ideal for targeting single gene mutations
- Mechanism of CNS gene delivery validated by preclinical and clinical data from MLD, MPS-I, MPS-IIIA
- Gene-modified HSCs enable delivery of *GRN* to brain

Knopman DS, Roberts RO. *J Mol Neurosci*. 2011, Onyike CU, Diehl-Schmid J. *Int Rev Psychiatry*. 2013 and Riedl L, et al *Neuropsychiatr Dis Treat*. 2014

Orchard therapeutics

HSC Gene Therapy: Advancing the Treatment Landscape in Immunological Disorders

Orchard therapeutics

Compelling Evidence in Immunological Disorders

OTL-103 for WAS
Moderate or severe bleeds



Elimination of severe bleeds

OTL-102 for X-CGD
Oxidase Activity



Functional neutrophils (above 10%) in 6 of 7 patients

Data presented at ASH 2019
Events per patient-year of observation for each observation period; GT, gene therapy; mo, months, N, number of patients; Y, years

Data published January 2020 in Nature Medicine
† patient deceased from advanced disease; Excludes data from 1 patient treated with drug product deemed by the investigator to be different from the OTL-102 drug product

Orchard therapeutics

HSC Transplants Give Rise to Tissue Macrophages with the Potential to Reconstitute Functional Gut Innate Immunity



Orchard therapeutics

Clinical Validation in X-CGD Supports Application in Larger Populations such as NOD2 Crohn's Disease



Orchard therapeutics™

OTL-104 for NOD2-Crohn's Represents a Significant Commercial Opportunity

THE OPPORTUNITY

NOD2-Crohn's
is a significant segment of Crohn's disease

- Up to 200,000 estimated patients with two mutated NOD2 alleles (7-10% of all Crohn's disease) in the U.S. and EU[1,2,3]
- NOD2-CD is increasingly recognized as a monogenic form of CD

OUR UNIQUE POSITIONING

Demonstrated potential of HSC gene therapy to treat other forms of colitis

- HSC GT and HSCT correct colitis in X-CGD + other monogenic PIDs
- NOD2-CD disorder of monocytes / macrophages in GI wall
- NOD2 patients often have severe relapsing disease despite immunosuppressive therapy
- Severe CD already associated with need for autologous HSCT

[1,2] CD prevalence estimates: Centers for Disease Control and Prevention; European Crohn's and Colitis Organisation (ECCO)
[3] NOD2: Ashton, James J et al.Clin Transl Gastroenterol. 2020 Feb

Orchard therapeutics

Operations and Upcoming Milestones

Orchard therapeutics

Today's Roadmap for a Sustainable Future

1	**Maintain Strong Balance Sheet**	• YE 2020 cash of $192M • Access equity markets following inflection points • Supplement with non-dilutive capital
2	**Invest for Growth**	• Focus on highest value programs • Allocate R&D capital for larger indications • Stage investments in additional rare disease programs
3	**Leverage Partnership Opportunities**	• Evaluate based on disease expertise and commercial footprint • Leverage HSC GT platform as engine for new indications

Orchard therapeutics™

2021 is Rich in Expected Milestones Spanning Development and Commercialization

Preclinical	Clinical	Regulatory	Commercial
OTL-204: Announce data from GRN-FTD research program **OTL-104:** Announce data from NOD2-CD research program	**OTL-203:** Initiate registrational study for MPS-I **OTL-201:** Complete enrollment in MPS-IIIA POC study Present interim data from **OTL-201** and **OTL-203** POC studies	**OTL-200:** Determine BLA filing strategy for MLD by mid-2021 **OTL-103:** Submit MAA filing for WAS by year-end 2021	**Libmeldy / OTL-200:** Launch in EU 1H 2021 **Libmeldy / OTL-200:** Leverage cross-border and treatment abroad reimbursement pathways in Europe, Middle East and Turkey

Building a fully integrated company

Orchard therapeutics

Compelling Fundamentals Driving Near and Long-term Growth

- **1x treatment** – HSC gene therapy approach offers curative potential
- **Strong clinical track record** – over 160 patients treated
- **Clinical validation** in rare diseases increases confidence for larger indications

libmeldy™
(Autologous CD34+ cells encoding ARSA gene)

now approved for early-onset MLD in the EU

$192M in cash as of YE 2020 and runway into the first half of 2022

Orchard therapeutics